help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 10, No. 10, 806-814, November 2005; doi:10.1634/theoncologist.10-10-806
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanz, M. A.
Right arrow Articles by Lo-Coco, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanz, M. A.
Right arrow Articles by Lo-Coco, F.

Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia

Miguel A. Sanza, Martin S. Tallmanb, Francesco Lo-Cococ

a Hematology Service, University Hospital La Fe, Valencia, Spain; b Division of Hematology/Oncology, Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; c Department of Biopathology, University "Tor Vergata", Rome, Italy

Key Words. Acute promyelocytic leukemia • All-trans retinoic acid • Anthracyclines • PML/RAR{alpha}

Correspondence: Miguel A. Sanz, M.D., Ph.D., Servicio de Hematología, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain. Telephone: +34-96-197 3057; Fax: +34-96-197 3281; e-mail: msanz{at}uv.es

Recent reviews on acute promyelocytic leukemia (APL) treatment have focused on comparing therapeutic approaches, including all-trans retinoic acid (ATRA) and chemotherapy, and do not address several other aspects of APL management that are relevant to the outcome in individual patients. These aspects include appropriate diagnostic tools and strategies, supportive care, recognition and treatment of life-threatening complications, evaluation of response, and, finally, management of the disease in special conditions such as older patients and pregnant women. In addition to reviewing current consensus and controversies of ATRA and chemotherapy treatment, this article addresses the above issues of APL management with special emphasis on aspects that distinguish APL from other acute myelogenous leukemias.




This article has been cited by other articles:


Home page
 ASH Education BookHome page
R. C. Ribeiro and E. Rego
Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration
Hematology, January 1, 2006; 2006(1): 162 - 168.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.